Fidarestat
 | |
| Names | |
|---|---|
| IUPAC name
(2S,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide | |
| Other names
(2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide | |
| Identifiers | |
| 105300-43-4 (unspecified) 136087-85-9; 105300-43-4 (unspecified) | |
| ChEMBL | ChEMBL84446 |
| UNII | 8SH8T1164U  |
| Properties | |
| C12H10FN3O4 | |
| Molar mass | 279.22 g/mol |
| Melting point | 290–300° |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Fidarestat (SNK-860) is an aldose reductase inhibitor used for treatment of diabetic neuropathy.
References
Aldose reductase inhibitor for treatment of diabetic complications. Prepn (stereo unspec): M. Kurono, et al., EP 193415; eidem, US 4740517 (1986, 1988 both to Sanwa). Prepn of isomers: T. Yamaguchi et al., Arzneim.-Forsch. 44, 344 (1994). Pharmacological profile: K. Mizuno et al. in Current Concepts of Aldose Reductase and Its Inhibitions, N. Sakamoto et al., Eds. (Elsevier, Amsterdam, 1990) pp 89-96. Configuration and crystal structure of complex with aldose reductase: M. Oka et al., J. Med. Chem. 43, 2479 (2000). Clinical efficacy in diabetic peripheral neuropathy: N. Hotta et al., Diabetes Care 24, 1776 (2001). Clinical suppression of sorbitol accumulation in erythrocytes of diabetic patients: T. Asano et al., J. Diabetes Complications 16, 133 (2002); eidem, ibid. 18, 336 (2004). Review of clinical development: N. Giannoukakis, Curr. Opin. Invest. Drugs 4, 1233-1239 (2003).